Article

Contact lens approved for use as bandage lens

A contact lens (Acuvue Oasis, Vistakon) has received FDA approval for therapeutic use as a bandage lens for certain acute and chronic ocular conditions.

Jacksonville, FL-A contact lens (Acuvue Oasis, Vistakon) has received FDA approval for therapeutic use as a bandage lens for certain acute and chronic ocular conditions.

"The wettability, smoothness, flexibility, high [level of] oxygen transmissibility, comfort, and Class I [ultraviolet light]-blocking properties of [the lens] make it an excellent choice for therapeutic use as a bandage lens for a range of conditions," said Sheila Hickson-Curran, director, medical affairs, Vistakon.

William B. Trattler, MD, a cornea specialist at the Center for Excellence in Eyecare, Miami, and a volunteer assistant professor at Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, said, "Under certain conditions, the use of a silicone hydrogel lens like [this lens] can help protect the cornea from exposure or repeated irritation often caused by rubbing during the wound-healing process and [can] assist in pain relief. For my patients, I have also found that [this lens] works wonderfully as a bandage contact lens for laser vision correction, as it reduces discomfort."

The recent FDA approval includes these uses:

The lens can be worn continuously for up to 6 nights and 7 days when used as a therapeutic lens. It also is indicated for daily wear vision correction and may be worn consecutively for up to 6 nights and 7 days of extended wear as recommended by an eye-care professional.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.